Xspray Pharma has now completed the population pharmacokinetic (PopPK) modeling that constitutes key regulatory documentation ...

In the course of the public share buyback offer by Medios AG announced on June 18, 2025, a total of 1,077,813 shares were tendered by the end of the acceptance period. The offer was made for up to ...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the initial investment capital from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd. (the "Investor"). On January 27, 2025, ...